Platelet Activation Is Not Involved in Acceleration of the Coagulation System in Acute Cardioembolic Stroke With Nonvalvular Atrial Fibrillation
- 1 August 1995
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 26 (8) , 1365-1368
- https://doi.org/10.1161/01.str.26.8.1365
Abstract
Background and Purpose It is generally accepted that the coagulation system is activated in ischemic stroke and that platelet activation is involved in the pathogenesis of this disease. However, little is known about how and to what extent platelet activity participates in coagulation system enhancement. We evaluated the hemostatic condition, especially with regard to platelet function and the coagulation system, within 3 days of onset of acute stroke. The study participants were limited to elderly patients with cardioembolic stroke due to nonvalvular atrial fibrillation. Methods Seventeen elderly patients with acute cardioembolic stroke due to nonvalvular atrial fibrillation were investigated. Within 3 days of stroke onset, β-thromboglobulin (BTG), platelet factor 4 (PF4), thrombin-antithrombin III complex (TAT), and d- dimer from arterial blood were carefully evaluated in these patients. Blood samples from 19 healthy age- and sex-matched control subjects were also examined. Results The two studied markers of platelet activity did not change in the patients or the control subjects, and the between-group differences between the stroke and control groups were not statistically significant (BTG, 43.8 versus 31.9 ng/mL; PF4, 9.06 versus 5.78 ng/mL; respectively). In contrast, the two studied coagulation-system indicators were markedly elevated in the patients compared with the control subjects (TAT, 13.8 versus 3.5 ng/mL, P <.01; d- dimer, 366.3 versus 147.2 ng/mL, P <.01; respectively). Conclusions Platelet function was not enhanced in the acute stage of cardioembolic stroke with nonvalvular atrial fibrillation. This result indicates that enhancement of the coagulation system in cardioembolic stroke is not the result of platelet hyperfunction, ie, “platelet-fibrin” thrombi, but rather of “stasis-related” thrombi formation.Keywords
This publication has 15 references indexed in Scilit:
- Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor strokeThe Lancet, 1993
- Alterations of haemostatic markers in various subtypes and phases of strokeBlood Coagulation & Fibrinolysis, 1993
- Hemostasis Variables in Type I Diabetic Patients Without Demonstrable Vascular ComplicationsDiabetes Care, 1993
- Alterations of Hemostatic Markers in Elderly Patient with Atrial Fibrillation without a History of Stroke.Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics, 1993
- Warfarin in the Prevention of Stroke Associated with Nonrheumatic Atrial FibrillationNew England Journal of Medicine, 1992
- The effect of antihypertensive drugs on in vivo platelet activity in essential hypertensionJournal Of Hypertension, 1992
- The Effect of Low-Dose Warfarin on the Risk of Stroke in Patients with Nonrheumatic Atrial FibrillationNew England Journal of Medicine, 1990
- Atrial Fibrillation — Risk Marker for StrokeNew England Journal of Medicine, 1990
- Altered Coagulation in Cerebral Ischemia Platelet, Thrombin, and Plasmin ActivityArchives of Neurology, 1990
- Beta-thromboglobulin in cerebral infarction.Journal of Neurology, Neurosurgery & Psychiatry, 1988